[go: up one dir, main page]

WO2007128923A3 - Procede de preparation d'un gel biocompatible a libération contrôlée d'un ou de plusieurs principes actifs peu solubles dans l'eau, gels ainsi obtenus et leur utilisation - Google Patents

Procede de preparation d'un gel biocompatible a libération contrôlée d'un ou de plusieurs principes actifs peu solubles dans l'eau, gels ainsi obtenus et leur utilisation Download PDF

Info

Publication number
WO2007128923A3
WO2007128923A3 PCT/FR2007/000781 FR2007000781W WO2007128923A3 WO 2007128923 A3 WO2007128923 A3 WO 2007128923A3 FR 2007000781 W FR2007000781 W FR 2007000781W WO 2007128923 A3 WO2007128923 A3 WO 2007128923A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
controlled release
gels
biocompatible
biocompatible gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/000781
Other languages
English (en)
Other versions
WO2007128923A2 (fr
Inventor
Laurence Hermitte
Molliard Samuel Gavard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anteis SA
Original Assignee
Anteis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anteis SA filed Critical Anteis SA
Publication of WO2007128923A2 publication Critical patent/WO2007128923A2/fr
Publication of WO2007128923A3 publication Critical patent/WO2007128923A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne un procédé de préparation d'un gel biocompatible à libération contrôlée d'un ou de plusieurs principes actifs lipophiles et/ou amphiphiles comportant une matrice à base d'un ou de plusieurs biopolymères fonctionnalisés ou non fonctionnalisés, dans lequel - dans une première étape, le ou les principes actifs lipophiles et/ou amphiphiles sont répartis de manière homogène, par dissolution dans un alcool biocompatible ou un mélange d'alcools biocompatibles, - dans une deuxième étape, le mélange homogène obtenu dans la première étape est mélangé à un gel biocompatible comportant une matrice de un ou plusieurs biopolymères fonctionnalisés ou non fonctionnalisés. Sont également décrits, les gels obtenus par le procédé de la présente invention et leur utilisation dans le domaine esthétique et thérapeutique.
PCT/FR2007/000781 2006-05-05 2007-05-07 Procede de preparation d'un gel biocompatible a libération contrôlée d'un ou de plusieurs principes actifs peu solubles dans l'eau, gels ainsi obtenus et leur utilisation Ceased WO2007128923A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0604068 2006-05-05
FR0604068A FR2900575B1 (fr) 2006-05-05 2006-05-05 Gel biocompatible a liberation controlee, son procede de preparation et son utilisation

Publications (2)

Publication Number Publication Date
WO2007128923A2 WO2007128923A2 (fr) 2007-11-15
WO2007128923A3 true WO2007128923A3 (fr) 2008-05-02

Family

ID=37603377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/000781 Ceased WO2007128923A2 (fr) 2006-05-05 2007-05-07 Procede de preparation d'un gel biocompatible a libération contrôlée d'un ou de plusieurs principes actifs peu solubles dans l'eau, gels ainsi obtenus et leur utilisation

Country Status (2)

Country Link
FR (1) FR2900575B1 (fr)
WO (1) WO2007128923A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9861570B2 (en) 2008-09-02 2018-01-09 Allergan Holdings France S.A.S. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US10080767B2 (en) 2003-04-10 2018-09-25 Allergan Industrie Sas Injectable monophase hydrogels
US10328180B2 (en) 2008-08-04 2019-06-25 Allergan Industrie, S.A.S. Hyaluronic acid-based gels including lidocaine
US10806821B2 (en) 2010-01-13 2020-10-20 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0819075A2 (pt) 2007-11-16 2014-10-07 Vicept Therapeutics Inc Método para tratar púrpura em um indivíduo e método para diminuir a púrpura em um indivíduo antes de um procedimento cirúrgico
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
FR2927255B1 (fr) * 2008-02-07 2011-08-12 Keysan Consulting Produits injectables biocompatibles a liberation de zinc et/ou de sel de saccharide sous forme de zinc et leurs utilisations.
FR2938187B1 (fr) 2008-11-07 2012-08-17 Anteis Sa Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaine, sterilisee a la chaleur
WO2010069519A1 (fr) * 2008-12-18 2010-06-24 Merz Pharma Gmbh & Co. Kgaa Compositions topiques comprenant au moins un ingrédient actif difficilement soluble dans l'eau et des biopolymères, tels que l'acide hyaluronique, présentant une valeur pka située entre 5 et 7
FR2945949B1 (fr) * 2009-05-26 2011-05-13 Anteis Sa Hydrogel injectable permettant une supplementation en glycerol dans la peau sur le long terme.
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
CA2792729C (fr) 2010-03-12 2016-06-28 Allergan Industrie, Sas Composition fluide pour l'amelioration d'etats cutanes
DK2550027T4 (da) 2010-03-22 2019-05-13 Allergan Inc Tværbundne polysaccharid- og protein-polysaccharid-hydrogeler til blødvævsforøgelse
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
EP3620184A1 (fr) 2014-09-30 2020-03-11 Allergan Industrie, SAS Compositions d'hydrogel stables comprenant des additifs
WO2016128783A1 (fr) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions et méthodes pour améliorer l'apparence de la peau
EP3653232A1 (fr) 2015-02-13 2020-05-20 Allergan Industrie, SAS Implants pour sculpter, augmenter ou corriger des caractéristiques faciales telles que le menton
US10004824B2 (en) 2015-05-11 2018-06-26 Laboratoires Vivacy Compositions comprising at least one polyol and at least one anesthetic
FR3036035B1 (fr) 2015-05-11 2018-10-05 Laboratoires Vivacy Compositions comprenant au moins un polyol et au moins un anesthesique
FR3058064B1 (fr) 2016-10-28 2020-08-07 Lab Vivacy Composition a base d'acide hyaluronique comprenant de la mepivacaine
CA3099732A1 (fr) 2018-05-09 2019-11-14 The Johns Hopkins University Composites nanofibres-hydrogel pour l'administration de cellules et de tissus
WO2019217767A1 (fr) 2018-05-09 2019-11-14 The Johns Hopkins University Composites de nanofibres-hydrogel pour le remplacement et la régénération améliorés de tissus mous
FR3111903B1 (fr) 2020-06-24 2022-12-02 Lab Vivacy Procede d’incorporation de composes organiques en solution au sein d’un hydrogel

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138029A2 (fr) * 1983-09-07 1985-04-24 Takeda Chemical Industries, Ltd. Composition pharmaceutique
WO2002011768A1 (fr) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Composition pour l'administration transdermique et/ou transmuqueuse de composes actifs assurant des niveaux d'efficacite therapeutique adequats
WO2002087563A2 (fr) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions et procedes pour le traitement d'etats inflammatoires par des proteines ou polysaccharides contenant des agents anti-microtubules
WO2003061626A1 (fr) * 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Systeme de gel polymere pour administration regulee de medicaments combines
WO2003105821A1 (fr) * 2002-06-12 2003-12-24 Orva Ilaç Sanayi Ve Ticaret A.S. Composition pharmaceutique comprenant un corticosteroide et un agent anti-inflammatoire non steroide
WO2005032514A1 (fr) * 2003-10-09 2005-04-14 Richter Gedeon Vegyészeti Gyár Rt. Composition pharmaceutique transdermique
WO2005039531A1 (fr) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Formulation pharmaceutique transdermique visant a reduire les residus sur la peau
US20050186261A1 (en) * 2004-01-30 2005-08-25 Angiotech International Ag Compositions and methods for treating contracture

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138029A2 (fr) * 1983-09-07 1985-04-24 Takeda Chemical Industries, Ltd. Composition pharmaceutique
WO2002011768A1 (fr) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Composition pour l'administration transdermique et/ou transmuqueuse de composes actifs assurant des niveaux d'efficacite therapeutique adequats
WO2002087563A2 (fr) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions et procedes pour le traitement d'etats inflammatoires par des proteines ou polysaccharides contenant des agents anti-microtubules
WO2003061626A1 (fr) * 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Systeme de gel polymere pour administration regulee de medicaments combines
WO2003105821A1 (fr) * 2002-06-12 2003-12-24 Orva Ilaç Sanayi Ve Ticaret A.S. Composition pharmaceutique comprenant un corticosteroide et un agent anti-inflammatoire non steroide
WO2005032514A1 (fr) * 2003-10-09 2005-04-14 Richter Gedeon Vegyészeti Gyár Rt. Composition pharmaceutique transdermique
WO2005039531A1 (fr) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Formulation pharmaceutique transdermique visant a reduire les residus sur la peau
US20050186261A1 (en) * 2004-01-30 2005-08-25 Angiotech International Ag Compositions and methods for treating contracture

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10080767B2 (en) 2003-04-10 2018-09-25 Allergan Industrie Sas Injectable monophase hydrogels
US10328180B2 (en) 2008-08-04 2019-06-25 Allergan Industrie, S.A.S. Hyaluronic acid-based gels including lidocaine
US9861570B2 (en) 2008-09-02 2018-01-09 Allergan Holdings France S.A.S. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US10806821B2 (en) 2010-01-13 2020-10-20 Allergan Industrie, Sas Heat stable hyaluronic acid compositions for dermatological use

Also Published As

Publication number Publication date
FR2900575B1 (fr) 2008-10-17
WO2007128923A2 (fr) 2007-11-15
FR2900575A1 (fr) 2007-11-09

Similar Documents

Publication Publication Date Title
WO2007128923A3 (fr) Procede de preparation d'un gel biocompatible a libération contrôlée d'un ou de plusieurs principes actifs peu solubles dans l'eau, gels ainsi obtenus et leur utilisation
ATE468111T1 (de) Zusammensetzung in mikropellets mit kontrollierter freisetzung von physiologischen wirksubstanzen, verfahren zu ihrer herstellung und ihre verwendung im zootechnischen sektor
EA200900270A1 (ru) Системы регулируемого высвобождения и способ их приготовления
AR062647A1 (es) Formulaciones farmaceutica y metodos de uso
WO2007044693A3 (fr) Compositions liquides, ioniques, multifonctionnelles pour vaincre le polymorphisme et conferer de meilleures proprietes a des ingredients actifs pharmaceutiques, biologiques, nutritionnels et energetiques
ATE495748T1 (de) Parasiticide formulierung und methode zur herstellung dieser formulierung
EP2422794A3 (fr) Compositions comprenant des cellules souches embryonnaires humaines et leurs dérivés, procédés d'utilisation et procédés de préparation
WO2001058474A3 (fr) Microencapsulation et liberation prolongee d'un agent biologiquement actif
MXPA05012821A (es) Formulacion farmaceutica que comprende un agente activo insoluble en agua.
WO2004026231A3 (fr) Preparation d'agents lipophiles
CN101563058A (zh) 有色的或可着色的能起泡的组合物和泡沫
MY143795A (en) Tetrahydropyridoindole derivatives
WO2007092620A3 (fr) Formulations stables et leurs procedes de preparation et d'utilisation
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
MY139427A (en) Controlled-release pharmaceutical composition and method for producing the same
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
WO2003035051A3 (fr) Utilisation d'agents sequestrants des protons dans des formulations medicamenteuses
NO20071354L (no) anvendelse av samme Butylftalid selvemulsifiserene medikamentavgivelsessystem, samt fremgangsmater for fremstilling og anvendelse av samme.
WO2001038303A3 (fr) Analogues de la vitamine d
BRPI0407181A (pt) Formulação farmacêutica
CN104622710A (zh) 水杨酸和脱乙酰壳多糖复配组合物的制备与应用
DE60211769D1 (de) Verfahren zur Herstellung von Arzneistoffgranulatkörnern, die Arzneistoffgranulatkörner sowie diese enthaltende pharmazeutische Zubereitungen
DK1450771T3 (da) Farmaceutiske præparater til behandling af hudlæsioner og slimhinder og fremgangsmåder og kits til anvendelse heraf
NO20031409L (no) Ionestyrkeuavhengig farmasoytiske preparat med langvarig frigivelse
EE05422B1 (et) Klaritromtsiini, rasv- ja hdrofiilse komponendi segu sisaldav farmatseutiline preparaat, meetod selle valmistamiseks ning kasutamine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07731423

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07731423

Country of ref document: EP

Kind code of ref document: A2